Vindesine, carmustine, doxorubicin, and prednisone (EBAP) in recurrent lymphomas: a Southwest Oncology Group study

• Published in: Cancer treatment reports Vol. 68; no. 7-8; p. 963
• Main Authors: Weick, J K, Jones, S E, Grozea, P N, Fabian, C J, Dixon, D O
• Format: Journal Article
• Language: English
• Published: United States 01-01-1984
• Subjects: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carmustine - administration & dosage; Carmustine - therapeutic use; Doxorubicin - administration & dosage; Doxorubicin - therapeutic use; Female; Humans; Lymphoma - drug therapy; Male; Middle Aged; Prednisone - administration & dosage; Prednisone - therapeutic use; Recurrence; Vinblastine - administration & dosage; Vinblastine - analogs & derivatives; Vinblastine - therapeutic use; Vindesine
• ISSN: 0361-5960

Seventy-eight patients with Hodgkin's disease and non-Hodgkin's lymphoma who had failed prior chemotherapy or radiation therapy were treated with a combination of vindesine, carmustine, doxorubicin, and prednisone (EBAP). Outpatient therapy was administered at 21-day intervals. Complete and partial responses were seen in 32 patients (41%). The response rate was higher for Hodgkin's disease (59%) than for non-Hodgkin's lymphoma (31%). The median duration of response was 31 weeks in both groups, with a median survival of all patients of 35 weeks (responders, 122 weeks; nonresponders, 16 weeks). Myelotoxicity was greater using EBAP than in the earlier reported program with vincristine, carmustine, doxorubicin, and prednisone, and in the absence of higher response rates does not support the use of vindesine over vincristine in combination programs using nitrosoureas, anthracyclines, and prednisone.